Upload
vuongphuc
View
215
Download
0
Embed Size (px)
Citation preview
TB Diagnostics: Global Market Analysis and Potential
Madhukar Pai, MD, PhD McGill University, Montreal, Canada [email protected] September 2012
2
Market analyses are important and necessary
• To support new product development
• To convince industries and investors about the need for investments in new TB tools
• To develop target product profiles (TPPs) that can guide product development and scale-up
• To inform donor/funder decisions
3
According to the World Health Organization, in 2010, there were ~9 million incident cases of TB Since ~7 - 10 people with TB symptoms need to be screened to detect one TB case, this means 60 - 90 million people get tested for active TB every year ~40% of this happens in India, China and South Africa In addition, there is testing for latent TB infection and MDR-TB
Source: WHO http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf
Global TB burden: how many people are screened for TB ever year?
4
By FIND & TDR Published in 2006
Source: FIND http://www.finddiagnostics.org/export/sites/default/resource-centre/find_documentation/pdfs/tbdi_full.pdf
Only one global TB market analysis has been done to date
5
• Annually over US$ 1 billion is spent worldwide on TB diagnostics
• One third (US$ 326 million)
of this money is spent out side of the established market economies (EME),where 73% of TB diagnostic testing takes place
• In EME: latent TB testing (PPD) dominates
• In non-EMEs: active TB
dominates (smears and chest x-rays)
Source: FIND/TDR, 2006
Findings from this analysis showed
6
• The potential markets for improved tests to detect active disease are large:
• 80 million for point-of-care test (per year) • 50 million for smear replacement (per year) • 20 million tests for culture replacement tests (per year)
Source: FIND/TDR, 2006
Potential market for new TB tests (global)
7
• Major recent changes in the TB dx landscape and policies
• Development of several new diagnostics that are replacing or supplementing older tests
• Shift from PPD skin testing to IGRAs in high income countries
• Donor-driven roll-out of new tools, especially molecular tests, in high burden countries
• Greater willingness of high burden countries (especially BRICS) to invest in new technologies and invest more in TB control
This global analysis needs to be updated to account for
8
The recently published UNITAID TB Dx landscape provides a good snapshot of this evolving landscape
http://www.unitaid.eu/marketdynamics/tuberculosis-diagnostic-landscape
9
Old tools are being replaced/supplemented by new technologies
Tuberculin IGRAs
Conventional microscopy
LED/FM microscopy
Solid cultures Liquid cultures
Conventional PCR
Cartridge-based NAATs
Molecular DST (LPA) Conventional, phenotypic DST
11 Denkinger C et al. Clin Micro Infect 2011
In high-income countries, there is a growing shift from tuberculin skin testing to IGRAs, or TST + IGRA
T-SPOT.TB® [Oxford Immunotec, UK]
QuantiFERON-TB Gold® In Tube [Cellestis Ltd, Qiagen]
12
For the first time, a molecular TB test is being rolled out for active TB in high burden countries; while sputum smears continue to be used
As of August 2012: $9.98 per cartridge for public sector in high burden countries
13
Source: Pai NP, Pai M. Discovery Med 2012
After GeneXpert, several fast-followers are rapidly emerging, aiming at decentralized deployment
14
Molecular diagnostics improve upon current tools, providing a bridge to true point-of-care Dx
Past and current
Long term future (10-15 years+ ?)
Expected health impact
This image cannot currently be displayed.
Microscopy • Very affordable • Poor sensitivity Culture • More expensive • Slow time to
result
Molecular diagnostics • Highly sensitive and
specific • Rapid time to results • Affordability and
accessibility increasing over time
True point-of-care Dx (based on biomarker
TBD) • High performance • Very affordable • Accessible even to
patients not reached by current Dx
Current and near term future
Next generation molecular Dx
GeneXpert
Source: ©BMGF
15
Efforts are ongoing to engage industries and donors in emerging economies (India and China, in particular) to develop affordable Dx that can be scaled-up for TB and HIV
Need for regional market analyses and focus on BRICS
TB Diagnostics in India: Market Analysis Revised - Version 2
Shekhar Menon, MBA [Indian Institute of Management, Bangalore] Minal Madhavankandi, MBA [Indian Institute of Management, Bangalore] Mansi Chitalia, MBA [Clinton Health Access Initiative, New Delhi] Madhukar Pai, MD, PhD* [McGill University, Montreal]
Full analysis is available at: http://tbevidence.org/resource-center/market-analyses/
17
Public sector (RNTCP) Private (non-RNTCP)
Refers to the testing facilities under the Revised National Tuberculosis Control Programme (RNTCP), the government tuberculosis programme
Includes all testing facilities in the private sector, government hospitals, medical colleges
TB diagnostics that are currently in use in India
• Active TB: • Sputum smear microscopy (direct
ZN staining) • Chest x-rays
• Drug resistant TB: • Line probe assays • Solid culture and DST • Liquid culture and DST
• Latent TB and pediatric TB: • Tuberculin skin test
• Active TB: • Sputum smear microscopy (direct
ZN and auramine staining) • Chest x-rays • Serological TB tests (ELISA and
rapid tests) • PCR (in-house or commercial) • QuantiFERON-TB Gold In Tube
• Drug resistant TB: • Line probe assays • Liquid culture and DST
• Latent TB: • Tuberculin skin test • QuantiFERON TB Gold In Tube
18
Estimation of number of patients with suspected pulmonary TB
Estimation of total pulmonary TB suspects (per year)
National TB programme (RNTCP) – Pulmonary TB suspects1 7,550,522
Contribution of RNTCP to total pulmonary suspects 40%
Contribution of Non RNTCP (private sector) to total pulmonary suspects 60%
Non RNTCP – Estimated number of pulmonary TB suspects 11,325,783
Total pulmonary TB suspects 18,876,305
Source: 1. RNTCP report: TB India 2011;
Assumptions based on discussions with key stakeholders*
Note: *Key stakeholders include RNTCP, WHO, BMGF, CHAI, FIND, GHS, private laboratory service providers, diagnostics manufacturers
• We assumed the split of patients tested for pulmonary TB (pulmonary TB suspects) in RNTCP: Non-RNTCP sector to be 40: 60 based on discussions with various stakeholders*
• The split was applied to the pulmonary TB suspects in the RNTCP sector to calculate the number of pulmonary TB suspects in the Non-RNTCP sector
19
Estimated RNTCP (public sector) spend on TB diagnosis
Source: 1. Discussions with RNTCP and labs 2.RNTCP report: TB India 2011; 3. Data from FIND and BD Note: Exchange rate: 1USD = 50 INR
TB test Volume Price per test1 ($)
Market value ($)
Comments
Sputum smear microscopy2
15,101,044 2.5 37,752,610 Assumes two smear conducted per suspect as per RNTCP diagnostic algorithm
Line Probe Assay (LPA)3
13,333 10.0 133,333
Liquid culture3 6,667 21.0 140,000
Total 15,121,044 38,025,943
• Based on RNTCP reporting and data from stakeholders, we noted the volumes of TB tests conducted by the RNTCP (public) sector
• Using the unit cost per test, we calculated the total patient spend on the various pulmonary TB tests
20
Estimated Non-RNTCP (private sector) spend on TB diagnosis
Source: : 1. Discussions with large lab chains Note: Exchange rate: 1USD = 50 INR
TB test Volume Price per test1 ($)
Market value ($)
Serology – Rapid Card tests (lateral flow assays) 3,397,735 5.0 16,988,675
Serology – ELISA (assumed 2 antibodies tested per suspect)
2,265,157 12.0 27,181,879
Sputum smear microscopy 2,831,446 2.5 7,078,614
Culture 1,132,578 33.0 37,375,084
PCR (in-house and commercial) 1,132,578 34.0 38,507,662
QuantiFERON-TB Gold In Tube 226,516 50.0 11,325,783
Line Probe Assay (LPA) 2,831 40.0 113,258
Total tests 10,988,841 138,570,955
• Unit cost per test was used to calculate the total patient spend on pulmonary TB diagnosis in the Non-RNTCP sector
21
Total patient spend on TB diagnosis in India: ~$220 m
TB testing in Volume Market value ($)
RNTCP 15,121,044 38,025,943
Non RNTCP 10,988,841 138,570,955
Common tests (X-rays and TST) 15,274,290 45,649,624
Total tests 41,384,175 222,246,522
India accounts for about 25% of the global TB burden
22
WHO has discouraged commercial TB serological tests and India has recently banned these tests
There is a substantial market now for a test that can replace TB serology
23
Replacement and usage scenarios to estimate addressable market value
Note: 1USD = 50 INR 1 No specific Target Product Profile (TPP) for the new TB test was assumed while developing the different scenarios 2 Assumes that the new TB test will be imported 3 Price to RNTCP assumes a discount of 10% on the cost to the labs, no lab overheads + margins and no referral fee to the providers; hence the difference between the RNTCP and Non-RNTCP price per test
Scenario (if a new TB test1 were to…) Volume Price per test2 ($)
Market value ($)
Replace serology (rapid + ELISA) (capture 33%) 1,868,754 23.4 43,728,844
Test always prescribed for all suspects (Ideal) 11,325,783 23.4 265,051,637
Test prescribed for 70% of suspects (High) 7,928,048 23.4 185,536,146
Test prescribed for 30% of suspects (Medium) 3,397,735 23.4 79,515,491
Test prescribed for 10% of suspects (Low) 1,132,578 23.4 26,505,164
Replace smear (capture 33%) 4,983,345 7.43 36,877,995
Replace smear (capture 100%) 15,101,044 7.43 111,751,501
Replace culture (capture 33%) 2,200 7.43 16,281
Replace culture (capture 100%) 6,667 7.43 49,335
Non
RN
TCP
RN
TCP
24
Some existing TPPs that need to be refined and integrated with market analyses to get at addressable market size
TPP for a POC test (MSF/TAG/STP)*
TPP for a simple and affordable molecular test
TPP for a high throughput molecular test for centralized laboratories
Note: *Batz H-G, Cooke GS, Reid SD. Towards lab-free tuberculosis diagnosis. http://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_Report_TowardsLabFreeTBDX_2011_ENG.pdf
© 2012 Bill & Melinda Gates Foundation | 25
Access to Care by Infrastructure Category* Region Access to no infrastructure Access to minimal
infrastructure Access to moderate/advanced
infrastructure
Africa 25% 47% 28%
Asia 13% 29% 58%
*Determining the Global Health Impact of Improved Diagnostic Technologies for the Developing World, Nature Supplement S1, p. 8
Current - Diagnostic Tools
Mid Term Goal - POC Platform with Moderate Impact
Far Term Goal - POC Platform with Significant Impact
Potential Coverage 28% - 58%
Potential Coverage 75% - 87%
Potential Coverage 87% - 93%
Globally, in the immediate term, we need an affordable molecular test that can be used in health centers with a peripheral lab
26
In the longer term, we need a simple POC test that can be deployed in the community and health posts
Pai NP, Vadnais C, Denkinger C, Engel N, et al. (2012) Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries. PLoS Med 9(9): e1001306. doi:10.1371/journal.pmed.1001306 http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001306
27
Conclusions
Although the exact size of the TB Dx global market today is not known, it is definitely likely to be higher than $1 billion because of two major trends in the past few years:
Tuberculin IGRAs
High income countries
Low/middle income countries
Microscopy Conventional DST
Molecular tests
$ $$$
28
Conclusions
However, since current versions of IGRAs and molecular tests are expensive and challenging to scale-up, there is an opportunity for companies to develop:
▫ More affordable IGRAs or next-generation assays for latent TB
infection that are more predictive for future disease
▫ More affordable molecular tests or next-generation assays for active TB and MDR-TB
▫ Truly innovative, simple technologies for POC use in decentralized settings
29
Chinese companies are already making progress along these lines
For example:
• TB-IGRAs by ▫ Beijing Wantai ▫ Haikou VTI Biological Institute ▫ Zhengzhou Biocell Biotechnology
• TB molecular assays by: ▫ Ustar Biotechnologies ▫ CapitalBio
• These products need to be internationally validated for policy recommendations and global uptake/adoption ▫ Regulatory approvals are required but not sufficient for policy and global scale-up
30
Which are the biggest markets for TB diagnostics? 30
For latent TB dx
For active TB dx
Canada: Health Canada USA: FDA >20 million tests for LTBI in North America
REGULATORY AGENCY & VOLUMES
India: Drug Controller General of India China: SFDA Brazil: ANVISA South Africa: Medicines Control Council 30 – 40 million tests for active TB in these countries
31
What evidence is needed for global policy? What are the challenges for global scale-up?
31
J Infect Dis 2012
Int J Tuberc Lung Dis 2012